Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P

§ 01 Executive Snapshot

• What: Elicio Therapeutics reported results from the Phase 2 AMPLIFY-7P trial for ELI-002 7P in mKRAS-driven pancreatic cancer.
• Who: Elicio Therapeutics, led by Robert Connelly (CEO) and Christopher Haqq (CMO).
• Why it matters: The trial's findings suggest potential for ELI-002 7P in a specific patient cohort, highlighting a significant unmet medical need in pancreatic cancer treatment.

§ 02 Key Developments

• The AMPLIFY-7P trial did not meet its primary endpoint of disease-free survival (DFS) in the intent-to-treat population.
• Post-hoc analysis showed a DFS hazard ratio of 0.65 (p=0.048) in the R0, completely resected population, indicating potential efficacy.
• mKRAS-specific T cell responses correlated strongly with DFS improvement (HR 0.22, p<0.0001), supporting the biological activity of ELI-002 7P.

§ 03 Strategic Context

• The AMPLIFY-7P trial enrolled 144 patients across 24 U.S. sites, focusing on patients with resected Stage I-III mKRAS-driven pancreatic ductal adenocarcinoma.
• The need for effective therapies post-surgery is critical, as there are currently no approved treatments following locoregional therapy for this patient population.

§ 04 Strategic Implications

• Immediate implications include a refined Phase 3 development strategy targeting the R0 resected population, potentially enhancing treatment outcomes.
• Long-term, successful results in the Phase 3 trial could position ELI-002 7P as a first-in-class immunotherapy for mKRAS-driven cancers, addressing a significant market opportunity.

§ 05 Risks & Constraints

• Potential risks include regulatory challenges in obtaining approval for ELI-002 7P based on the Phase 2 results and the need for further validation in Phase 3.
• The competitive landscape for cancer immunotherapies is intense, with numerous companies developing similar therapies, which may impact Elicio's market positioning.

§ 06 Watchlist / Forward Signals

• The company plans to initiate a Phase 3 study focusing on R0 resected patients, with enrollment expected to begin pending financing.
• Key milestones will include regulatory discussions and the initiation of the Phase 3 trial, which will be critical for determining the future of ELI-002 7P in the market.